Related Experiment Videos
Antisense oligonucleotide therapy in urology
1Department of Immunology and Cell Biology, Research Center Borstel, Borstel, Germany.
The Journal of Urology
|June 7, 2002
Summary
Antisense oligonucleotides show promise for treating urological cancers by inhibiting protein synthesis. Early clinical trials demonstrate safety, but further research is needed to overcome delivery and stability challenges for widespread medical application.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Antisense oligonucleotides are modified DNA/RNA molecules targeting messenger RNA to inhibit protein synthesis.
- Antisense technology has advanced significantly over the past two decades, particularly in cancer treatment strategies.
Purpose of the Study:
- To provide urologists with an updated review of antisense oligonucleotide therapy for urological tumors.
- To outline current treatment strategies and ongoing clinical trials involving antisense agents in urology.
Main Methods:
- A comprehensive literature review of preclinical and clinical studies.
- Searches included PubMed and proceedings from international scientific meetings.
Main Results:
- Preclinical strategies focus on inhibiting proliferation, inducing differentiation and apoptosis, and reversing tumor-induced immunosuppression.
- Phosphorothioate oligonucleotides have shown efficacy in preclinical cancer models.
- Clinical trials are evaluating antisense agents targeting c-raf kinase, protein kinase C-alpha, protein kinase A, and bcl-2 in urological tumors.
Conclusions:
- Antisense compounds effectively reduce target messenger RNA and protein expression in vitro.
- Early clinical trials indicate that antisense agents are safe with mild toxicity at tested doses.
- Significant obstacles including nuclease stability, affinity, cellular delivery, and specificity must be addressed for broader medical application.